Novacyt announces update on strategic review of non-core assets

Novacyt announces update on strategic review of non-core assets NOVAprep® and clinical laboratory enter formal sales process Novacyt to enhance focus on core profitable diagnostic products business

Visit Page

Completion of substantial q16 molecular diagnostics order expands clinical diagnostic reach in fast growing Chinese market

Novacyt q16 order in China Paris, France and Camberley, UK – 6th December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign’s q16 molecular instruments from a new customer within the fast growing Chinese market. The order for 100 molecular

Visit Page

NOVACYT SIGNS $3.0M DIAGNOSTICS SUPPLY AGREEMENT WITH GENESIS DIAGNOSTICS

PrimerDesign Genesis Diagnostics ENG Paris, France and Camberley, UK – 27th November 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has signed an exclusive supply agreement worth a minimum of $3 million with Genesis Diagnostics, a US-based full service diagnostic

Visit Page